It is anticipated that the legionnaire disease testing market would expand at a compound annual growth rate (CAGR) of 9%, from US$ 292 million in 2022 to US$ 819.5 million in 2032. A serious kind of pneumonia infection that inflames the lungs is called legionnaire’s disease. Legionella is the bacteria that causes legionnaire’s disease. It …